A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Trial)

@article{Hamaguchi2011API,
  title={A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Trial)},
  author={Tetsuya Hamaguchi and Kuniaki Shirao and Atsushi Ohtsu and Ichinosuke Hyodo and Yasuaki Arai and Hiroya Takiuchi and Hirofumi Fujii and Motoki Yoshida and Hiroshi Saito and Tadamichi Denda and Wasaburo Koizumi and Hiroaki Iwase and Narikazu Boku},
  journal={Gastric Cancer},
  year={2011},
  volume={14},
  pages={226-233}
}
Preclinical studies have shown that mitomycin C (MMC) acts synergistically with irinotecan (CPT-11). In this phase II study, we evaluated the efficacy and toxicity of MMC/CPT-11 therapy as second-line chemotherapy for patients with fluoropyrimidine-resistant advanced gastric cancer. Eligible patients had evidence of tumor progression despite prior treatment with fluoropyrimidine-based regimens or had relapsed within 6 months after completion of therapy with adjuvant fluoropyrimidines. Treatment… CONTINUE READING
7 Citations
43 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-7 of 7 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 43 references

Similar Papers

Loading similar papers…